| Tbio | Tryptophan--tRNA ligase, cytoplasmic |
Isoform 1, isoform 2 and T1-TrpRS have aminoacylation activity while T2-TrpRS lacks it. Isoform 2, T1-TrpRS and T2-TrpRS possess angiostatic activity whereas isoform 1 lacks it. T2-TrpRS inhibits fluid shear stress-activated responses of endothelial cells. Regulates ERK, Akt, and eNOS activation pathways that are associated with angiogenesis, cytoskeletal reorganization and shear stress-responsive gene expression.
Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Two forms of tryptophanyl-tRNA synthetase exist, a cytoplasmic form, named WARS, and a mitochondrial form, named WARS2. Tryptophanyl-tRNA synthetase (WARS) catalyzes the aminoacylation of tRNA(trp) with tryptophan and is induced by interferon. Tryptophanyl-tRNA synthetase belongs to the class I tRNA synthetase family. Four transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Two forms of tryptophanyl-tRNA synthetase exist, a cytoplasmic form, named WARS, and a mitochondrial form, named WARS2. Tryptophanyl-tRNA synthetase (WARS) catalyzes the aminoacylation of tRNA(trp) with tryptophan and is induced by interferon. Tryptophanyl-tRNA synthetase belongs to the class I tRNA synthetase family. Four transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Thyroid cancer, papillary | 14 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| psoriasis | 6694 | 8.1e-08 |
| juvenile dermatomyositis | 1187 | 1.7e-07 |
| ovarian cancer | 8520 | 3.0e-05 |
| sarcoidosis | 370 | 1.0e-04 |
| interstitial cystitis | 2312 | 6.7e-04 |
| Breast cancer | 3578 | 2.5e-03 |
| dermatomyositis | 966 | 4.2e-03 |
| lung cancer | 4740 | 4.7e-03 |
| active Crohn's disease | 922 | 5.1e-03 |
| cutaneous lupus erythematosus | 1057 | 1.1e-02 |
| Chronic Lymphocytic Leukemia | 262 | 1.5e-02 |
| esophageal adenocarcinoma | 737 | 1.8e-02 |
| subependymal giant cell astrocytoma | 2287 | 1.9e-02 |
| active ulcerative colitis | 764 | 1.9e-02 |
| MYELODYSPLASTIC SYNDROME | 53 | 3.5e-02 |
| head and neck cancer and chronic obstructive pulmonary disease | 239 | 4.7e-02 |
| glioblastoma | 5792 | 4.9e-02 |
| Disease | log2 FC | p |
|---|---|---|
| active Crohn's disease | 1.904 | 5.1e-03 |
| active ulcerative colitis | 1.541 | 1.9e-02 |
| Breast cancer | 1.100 | 2.5e-03 |
| Chronic Lymphocytic Leukemia | 1.562 | 1.5e-02 |
| cutaneous lupus erythematosus | 1.700 | 1.1e-02 |
| dermatomyositis | 1.700 | 4.2e-03 |
| esophageal adenocarcinoma | 1.500 | 1.8e-02 |
| glioblastoma | 1.600 | 4.9e-02 |
| head and neck cancer and chronic obstruc... | 1.400 | 4.7e-02 |
| interstitial cystitis | 2.200 | 6.7e-04 |
| juvenile dermatomyositis | 1.317 | 1.7e-07 |
| lung cancer | -1.300 | 4.7e-03 |
| MYELODYSPLASTIC SYNDROME | -1.100 | 3.5e-02 |
| ovarian cancer | 2.100 | 3.0e-05 |
| psoriasis | 1.200 | 8.1e-08 |
| sarcoidosis | 1.100 | 1.0e-04 |
| subependymal giant cell astrocytoma | 1.946 | 1.9e-02 |
MPNSEPASLLELFNSIATQGELVRSLKAGNASKDEIDSAVKMLVSLKMSYKAAAGEDYKADCPPGNPAPT 1 - 70 SNHGPDATEAEEDFVDPWTVQTSSAKGIDYDKLIVRFGSSKIDKELINRIERATGQRPHHFLRRGIFFSH 71 - 140 RDMNQVLDAYENKKPFYLYTGRGPSSEAMHVGHLIPFIFTKWLQDVFNVPLVIQMTDDEKYLWKDLTLDQ 141 - 210 AYSYAVENAKDIIACGFDINKTFIFSDLDYMGMSSGFYKNVVKIQKHVTFNQVKGIFGFTDSDCIGKISF 211 - 280 PAIQAAPSFSNSFPQIFRDRTDIQCLIPCAIDQDPYFRMTRDVAPRIGYPKPALLHSTFFPALQGAQTKM 281 - 350 SASDPNSSIFLTDTAKQIKTKVNKHAFSGGRDTIEEHRQFGGNCDVDVSFMYLTFFLEDDDKLEQIRKDY 351 - 420 TSGAMLTGELKKALIEVLQPLIAEHQARRKEVTDEIVKEFMTPRKLSFDFQ 421 - 471 //
